Physician profile
Randall Ruppel
NPI 1598749384
$2,783.39
in general payments reported to CMS, 2019-2025
18 companies · $412 in 2025
The $412 reported for 2025 was more than what 84% of Pediatric Critical Care Medicine providers received nationally (typical 2025 total: $71.68).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $35.39 · 2021: $143 · 2022: $714 · 2023: $755 · 2024: $600 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,655 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,654.69 |
| Education | $111.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $737.98 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $594.87 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $323.82 | 2022-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $275.24 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $218.77 | 2022-2025 | Caplyta |
| Lundbeck LLC | $152.38 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $129.16 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $71.31 | 2024 | Fanapt, Hetlioz |
| Abbvie INC. | $52.57 | 2023-2024 | Vraylar |
| Idorsia Pharmaceuticals US INC | $47.48 | 2023-2024 | Quviviq |
| Corium, LLC | $34.30 | 2023-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $29.52 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $21.90 | 2024 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $21.79 | 2024 | Trintellix |
| Uswm, LLC | $21.37 | 2024 | Lucemyra |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $17.94 | 2025 | Jornay Pm |
| Alkermes, INC. | $17.03 | 2025 | Aristada, Lybalvi |
| Novo Nordisk INC | $15.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Ruppel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.